Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 51.06 -0.39% -0.20
EGRX closed down 1.27 percent on Friday, May 29, 2020, on approximately normal volume. It was able to find support at its 50 day moving average. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down
Historical EGRX trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish -0.39%
Hammer Candlestick Bullish -0.39%
Lizard Bullish Bullish Day Trade Setup -0.39%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.39%
Multiple of Ten Bullish Other -0.39%
Down 3 Days in a Row Weakness -0.39%
Gapped Down Weakness -0.39%
Lower Bollinger Band Touch Weakness -0.39%
Fell Below 20 DMA Bearish -1.66%
Inside Day Range Contraction -1.66%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
Medicine Chemistry Pharmaceutical Lymphoma Organic Chemistry Chronic Lymphocytic Leukemia Lung Cancer Treatment Of Chronic Lymphocytic Leukemia Heparin Induced Thrombocytopenia Injectable Products Nitrogen Mustards

Is EGRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 64.94
52 Week Low 33.8
Average Volume 156,147
200-Day Moving Average 54.52
50-Day Moving Average 49.30
20-Day Moving Average 53.10
10-Day Moving Average 53.02
Average True Range 2.16
ADX 15.13
+DI 21.61
-DI 30.22
Chandelier Exit (Long, 3 ATRs ) 49.68
Chandelier Exit (Short, 3 ATRs ) 55.74
Upper Bollinger Band 55.42
Lower Bollinger Band 50.78
Percent B (%b) 0.1
BandWidth 8.74
MACD Line 0.64
MACD Signal Line 1.08
MACD Histogram -0.4348
Fundamentals Value
Market Cap 777.56 Million
Num Shares 15.2 Million
EPS 5.96
Price-to-Earnings (P/E) Ratio 8.60
Price-to-Sales 3.34
Price-to-Book 4.96
PEG Ratio 0.95
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 55.19
Resistance 3 (R3) 54.96 53.42 54.54
Resistance 2 (R2) 53.42 52.42 53.54 54.32
Resistance 1 (R1) 52.34 51.80 51.57 52.57 54.10
Pivot Point 50.80 50.80 50.42 50.92 50.80
Support 1 (S1) 49.72 49.80 48.95 49.95 48.42
Support 2 (S2) 48.18 49.18 48.30 48.20
Support 3 (S3) 47.10 48.18 47.99
Support 4 (S4) 47.33